Viewing nowCombinationSitaplus Tablet 50/1000 Milligrams (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
CMG Pharmaceuticals Co., Ltd.

MFDS item code 202301800 · Approved 2023.06.12 · Insurance code 648604520
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood glucose control for patients with type 2 diabetes. Sitagliptin and Metformin work together to complement the effects of dietary and exercise regimens. This helps improve blood glucose levels and manage diabetes effectively. It is a drug that helps improve the patient's blood glucose control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains both Sitagliptin and Metformin and is used for the treatment of type 2 diabetes. First, a severe allergic reaction may occur while taking this medication; therefore, if you experience symptoms such as skin rash, difficulty breathing, or swelling of the face or neck, you should stop taking the medication immediately and consult a doctor. In addition, this medication can cause inflammation of the pancreas (pancreatitis), so if you experience symptoms like abdominal pain, vomiting, or nausea, you should inform medical personnel immediately. Due to the Metformin component, a rare but potentially life-threatening condition known as lactic acidosis may occur, so if you experience sudden difficulty breathing, muscle pain, fatigue, or abdominal pain, stop taking this medication immediately and visit a hospital. Patients with poor kidney function, severe infections, dehydration, heart failure, acute myocardial infarction, or sepsis should not take this medication. You should also temporarily stop taking this medication before and after tests using iodine-based contrast agents, and restart only after confirming normal kidney function after the test. It is safer not to take this medication during pregnancy or if you are possibly pregnant, and nursing mothers should also avoid it. Be cautious of the risk of hypoglycemia when your meal intake is irregular or insufficient or when engaging in vigorous exercise while on this medication. The symptoms of hypoglycemia may be more pronounced if taken with other glucose-lowering agents. Additionally, patients with impaired liver function or who excessively consume alcohol should avoid taking this medication as well. Regular monitoring of kidney function and blood tests should be performed to ensure the safety of using this medication, and periodic checks of vitamin B12 levels are recommended. If undergoing surgery, you should stop taking this medication 48 hours before the surgery and restart after confirming normal kidney function post-surgery and when oral intake has resumed. Finally, caution is necessary when performing activities that require alertness, such as operating machinery or driving, due to the possibility of hypoglycemia or lactic acidosis from taking this medication. Lastly, while taking this medication, there is a possibility of drug interactions, so it is essential to inform your doctor or pharmacist of any other medications you are taking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure and is best kept at temperatures between 1 degree and 30 degrees Celsius. Storing it this way helps maintain the effectiveness of the medication.
Oval film-coated tablet, reddish-brown
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
CMG Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.